tiprankstipranks
Advertisement
Advertisement

NVS Stock Latest News

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme
The FlyH.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme
18h ago
MRK
NVS
Alteogen enters option, license agreement with Novartis
PremiumThe Fly
Alteogen enters option, license agreement with Novartis
23h ago
NVS
Novartis Maintained at Buy as Strong Remibrutinib Phase 3 Data Support RMS Opportunity; $135 Price Target Unchanged
PremiumRatings
Novartis Maintained at Buy as Strong Remibrutinib Phase 3 Data Support RMS Opportunity; $135 Price Target Unchanged
1d ago
NVS
Midday Fly By: Medtronic reports Q1 beat, Ternus takes over as Apple CEO
PremiumThe Fly
Midday Fly By: Medtronic reports Q1 beat, Ternus takes over as Apple CEO
2d ago
CRK
CVX
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
PremiumThe Fly
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
2d ago
NVS
CHRO
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
PremiumMarket NewsNovartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
2d ago
NVS
SNY
Unusually active option classes on open September 1st
Premium
The Fly
Unusually active option classes on open September 1st
2d ago
TE
HWM
Morning Movers: Fervo Energy boosted by power purchase agreement with Google
Premium
The Fly
Morning Movers: Fervo Energy boosted by power purchase agreement with Google
2d ago
MU
MDT
Remibrutinib’s Strong Phase III Results and Robust Novartis Pipeline Underpin Unchanged CHF 140 Buy Rating
PremiumRatings
Remibrutinib’s Strong Phase III Results and Robust Novartis Pipeline Underpin Unchanged CHF 140 Buy Rating
2d ago
NVS
Novartis Reports Positive Phase III Results for Oral BTK Inhibitor Remibrutinib in Relapsing Multiple Sclerosis
PremiumCompany Announcements
Novartis Reports Positive Phase III Results for Oral BTK Inhibitor Remibrutinib in Relapsing Multiple Sclerosis
2d ago
6K
NVS
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
PremiumThe Fly
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
2d ago
NVS
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
PremiumThe Fly
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
2d ago
BMY
NVS
Vanguard Dividend ETFs Comparison: VYMI vs. VIG vs. VYM for Income Investors
PremiumMarket NewsVanguard Dividend ETFs Comparison: VYMI vs. VIG vs. VYM for Income Investors
9d ago
JPM
NVS
3 Stocks Under $10 With Over 100% Upside, According to Analysts
Premium
Market News
3 Stocks Under $10 With Over 100% Upside, According to Analysts
12d ago
LLY
NVS
Novartis’ iptacopan granted FDA orphan designation
Premium
The Fly
Novartis’ iptacopan granted FDA orphan designation
15d ago
NVS
3 Dividend ETFs Crushing the S&P 500 in 2026
PremiumMarket News
3 Dividend ETFs Crushing the S&P 500 in 2026
17d ago
VZ
CVX
SCHD vs. VYMI vs. VIG: Which Is the Best Dividend ETF for Passive Income Investors?
PremiumMarket News
SCHD vs. VYMI vs. VIG: Which Is the Best Dividend ETF for Passive Income Investors?
22d ago
HD
ABT
3 Vanguard Dividend ETFs to Boost Passive Income
PremiumMarket News
3 Vanguard Dividend ETFs to Boost Passive Income
24d ago
NVS
HSBC
Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook
PremiumRatings
Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook
27d ago
NVS
Amgen price target raised to $351 from $333 at Morgan Stanley
PremiumThe FlyAmgen price target raised to $351 from $333 at Morgan Stanley
29d ago
NVS
AMGN
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
Premium
The Fly
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
1M ago
NVS
SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?
Premium
Market News
SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?
1M ago
ABT
MRK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >